紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Nuclear Factor, Erythroid Derived 2 Like Protein 2 (NFE2L2) ,etc. by FLIA (Flow Luminescence Immunoassay)
NRF2; HEBP1; NF-E2-Related Factor 2; Nuclear factor, erythroid derived 2, like 2
（注：?jiǎn)未位鞙y(cè)多因子不超過(guò)8個(gè)指標(biāo) ）
- 編號(hào)LML947Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3.5h
- 檢測(cè)范圍0.01-10ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.003 ng/mL.
- 樣本類型Tissue homogenates, cell lysates and other biological fluids.
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2883 ¥ 2994 ¥ 3160 ¥ 3382 ¥ 3604 ¥ 3936 ¥ 4435 ¥ 5544 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 79-91 | 84 |
| EDTA plasma(n=5) | 78-89 | 82 |
| heparin plasma(n=5) | 90-97 | 93 |
| sodium citrate plasma(n=5) | 85-103 | 89 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 87-98% | 78-101% | 94-105% | 95-103% |
| EDTA plasma(n=5) | 90-104% | 96-104% | 93-101% | 94-103% |
| heparin plasma(n=5) | 79-93% | 92-105% | 90-101% | 85-94% |
| sodium citrate plasma(n=5) | 79-91% | 82-93% | 88-96% | 93-101% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測(cè)溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測(cè)溶液B100μL，37°C振動(dòng)孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPL947Hu01 | 紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAL947Hu01 | 紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)多克隆抗體 | WB; IHC; ICC; IP. |
| MAL947Hu21 | 紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)單克隆抗體 | WB; IHC; ICC; IP. |
| SEL947Hu | 紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LML947Hu | 紅細(xì)胞衍生核因子2樣蛋白2(NFE2L2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Peptides. | Carnosine ameliorates cognitive deficits in streptozotocin-induced diabetic rats: Possible involved mechanisms. [pubmed:27777064] |
| european journal of pharmacology | Garlic active constituent s-allyl cysteine protects against lipopolysaccharide-induced cognitive deficits in the rat: Possible involved mechanisms. [pubmed:27915041] |
| european journal of pharmacology | S-allyl cysteine ameliorates cognitive deficits in streptozotocin-diabetic rats via suppression of oxidative stress, inflammation, and acetylcholinesterase. [pubmed:27887948] |
| Psychopharmacology (Berl) | Ellagic acid ameliorates learning and memory deficits in a rat model of Alzheimer's disease: an exploration of underlying mechanisms. [pubmed:28303372] |
| brain research | Ellagic acid exerts protective effect in intrastriatal 6-hydroxydopamine rat model of Parkinson's disease: Possible involvement of ERβ/Nrf2/HO-1 signaling. [pubmed:28238669] |
| Inflammopharmacology. | Implication of Nrf2/HO-1 pathway in the coloprotective effect of coenzyme Q10 against experimentally induced ulcerative colitis. [pubmed:28050757] |
| Biomedicine & Pharmacotherapy | Ameliorative potential of sitagliptin and/or resveratrol on experimentallyinduced clear cell renal cell carcinoma [pubmed:29101811] |
| Asian Pacific Journal of Cancer Prevention | Ameliorative Effect of Coenzyme Q10 and/or Candesartan on Carboplatin-Induced Nephrotoxicity: Roles of Apoptosis, Transforming Growth Factor-Β1, Nuclear Factor Kappa-B And The Nrf2/HO-1 Pathway [pubmed:28670881] |
| Nutrients | Effect of Green and Brown Propolis Extracts on the Expression Levels of microRNAs, mRNAs and Proteins, Related to Oxidative Stress and Inflammation. [pubmed:28974022] |
| Cytokine | Soy isoflavone genistein attenuates lipopolysaccharide-induced cognitive impairments in the rat via exerting anti-oxidative and anti-inflammatory effects [pubmed:29102164] |
| Biomedicine & pharmacotherapy | Berberine ameliorates intrahippocampal kainate-induced status epilepticus and consequent epileptogenic process in the rat: Underlying mechanisms [pubmed:28061403] |
| International Immunopharmacology | Scutellarin alleviates lipopolysaccharide-induced cognitive deficits in the rat: Insights into underlying mechanisms. [pubmed:29190543] |
| Neurotoxicology | Molecular mechanisms of neuroprotective effect of adjuvant therapy with phenytoin in pentylenetetrazole-induced seizures: impact on Sirt1/NRF2 signaling pathways [Pubmed:30017425] |
| Biomedicine & Pharmacotherapy | Targeting Nrf2/HO-1 signaling by crocin: Role in attenuation of AA-induced ulcerative colitis in rats [Pubmed: 30530041] |
| Toxicology Reports | IL-6 and NFE2L2: A putative role for the hepatoprotective effect of N. Sativa, P. Ginseng and C. Sempervirens in AFB-1 induced hepatocellular carcinoma in?… [] |
| Redox Biology | Short-term pharmacological activation of Nrf2 ameliorates vascular dysfunction in aged rats and in pathological human vasculature. A potential target for?… [Pubmed: 31302408] |
| Life Sciences | Crocin attenuates lung inflammation and pulmonary vascular dysfunction in a rat model of bleomycin-induced pulmonary fibrosis [Pubmed: 31465731] |
| Respiratory physiology & neurobiology | Targeting oxidative stress, proinflammatory cytokines, apoptosis and toll like receptor 4 by empagliflozin to ameliorate bleomycin-induced lung fibrosis [Pubmed: 31600583] |
| NAUNYN-SCHMIEDEBERGS?ARCHIVES OF?PHARMACOLOGY | Effects of repeated increasing doses of cisplatin as models of acute kidney injury and chronic kidney disease in rats [Pubmed: 32936352] |
| Iranian Journal of Medical Sciences | Esculetin Alleviates Acute Liver Failure following Lipopolysaccharide/D-Galactosamine in Male C57BL/6 Mice [] |
| Can J Physiol Pharmacol | Taurine alleviates kidney injury in a thioacetamide rat model by mediating Nrf2/HO-1, NQO-1 and MAPK/NF-κB signaling pathways [34695366] |
